Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development

The coronavirus disease 2019 (COVID-19) is a respiratory disease with a very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 is easy to mutate, the continuous emergence of SARS-CoV-2 variant strains not only enhances the infectivity...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024-11, Vol.15, p.1407149
Main Authors: Huan, Xinkang, Zhan, Jiuyu, Gao, Hongwei
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - immunology
Antibodies, Viral - therapeutic use
antibody
COVID-19
COVID-19 - immunology
COVID-19 - virology
Humans
Immunology
inevitability
Mutation
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
variants
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coronavirus disease 2019 (COVID-19) is a respiratory disease with a very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 is easy to mutate, the continuous emergence of SARS-CoV-2 variant strains not only enhances the infectivity of the SARS-CoV-2 but also brings great obstacles to the treatment of COVID-19. Neutralizing antibodies have achieved good results in the clinical application of the novel coronavirus pneumonia, which can be used for pre-infection protection and treatment of novel coronavirus patients. This review makes a detailed introduction to the mutation characteristics of SARS-CoV-2, focusing on the molecular mechanism of mutation affecting the infectivity of SARS-CoV-2, and the impact of mutation on monoclonal antibody therapy, providing scientific reference for the prevention of SARS-CoV-2 variant strains and the research and development of antibody drugs.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1407149